Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis

Bone

Volumn 39, Issue 6, 2006, Pages 1268-1275

  Gallagher, J C ^a   Rosen, C J ^b   Chen, P ^c   Misurski, D A ^c   Marcus, R ^c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b ST JOSEPH HOSPITAL   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Alendronate; Biochemical markers of bone turnover; Bone mineral density; Responder analysis; Teriparatide

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34];

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL; SAFETY; TERIPARATIDE;

EID: 37849184955     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.06.007     Document Type: Article

References (33)

1. Miller P.D. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr. Osteoporos. Rep. 3 (2005) 103-110
2. Miller P.D., Hochberg M.C., Wehren L.E., Ross P.D., and Wasnich R.D. How useful are measures of BMD and bone turnover?. Curr. Med. Res. Opin. 21 (2005) 545-554
3. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 112 (2002) 281-289
4. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 17 (2002) 1-10
5. Li Z., Meredith M.P., and Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat. Med. 20 (2001) 3175-3188
6. Ravaud P., Reny J.L., Giraudeau B., Porcher R., Dougados M., and Roux C. Individual smallest detectable difference in bone mineral density measurements. J. Bone Miner. Res. 14 (1999) 1449-1456
7. Lewiecki E.M. Nonresponders to osteoporosis therapy. J. Clin. Densitom. 6 (2003) 307-314
8. Bonnick S.L., Johnston C.C., Kleerekoper M., Lindsay R., Miller P., Sherwood L., et al. Importance of precision in bone density measurements. J. Clin. Densitom. 4 (2001) 105-110
9. Gluer C.C. Monitoring skeletal changes by radiological techniques. J. Bone Miner. Res. 14 (1999) 1952-1962
10. Lenchik L., Kiebzak G.M., and Blunt B.A. What is the role of serial bone mineral density measurements in patient management?. J. Clin. Densitom. 5 (2002) S29-S38 (Suppl.)
11. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
12. McClung M.R., San Martin J., Miller P.D., Civitelli R., Bandeira F., Omizo M., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165 (2005) 1762-1768
13. Body J.J., Gaich G.A., Scheele W.H., Kulkarni P.M., Miller P.D., Peretz A., et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87 (2002) 4528-4535
14. Lu Y., Ye K., Mathur A.K., Hui S., Fuerst T.P., and Genant H.K. Comparative calibration without a gold standard. Stat. Med. 16 (1997) 1889-1905
15. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18 (2003) 1051-1056
16. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20 (2005) 962-970
17. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., and Karpf D.B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J. Bone Miner. Res. 13 (1998) 1431-1438
18. Ravn P., Clemmesen B., and Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24 (1999) 237-244
19. Hannon R., Blumsohn A., Naylor K., and Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J. Bone Miner. Res. 13 (1998) 1124-1133
20. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
21. Cummings S.R., Bates D., and Black D.M. Clinical use of bone densitometry: scientific review. JAMA 288 (2002) 1889-1897
22. Patel R., Blake G.M., Rymer J., and Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos. Int. 11 (2000) 68-75
23. Dobnig H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J. Clin. Endocrinol. Metab. 90 (2005) 3970-3977
24. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., and Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 12 (2001) 922-930
25. Sarkar S., Reginster J.Y., Crans G.C., Diez-Perez A., Pinette K., and Delmas P. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J. Bone Miner. Res. 19 (2004) 394-401
26. Bauer D.C., Black D., Garnero P., Hochberg M., Ott S.M., Schneider D.L., et al. Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: The Fracture Intervention Trial. Osteoporos. Int. 13 Suppl 1 (2004) S521
27. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18 (2003) 1051-1056
28. Reginster J.Y., Sarkar S., Zegels B., Henrotin Y., Bruyere O., Agnusdei D., et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34 (2004) 344-351
29. Ettinger B., San Martin J., Crans G., and Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19 (2004) 745-751
30. Deal C., Omizo M., Schwartz E.N., Eriksen E.F., Cantor P., Wang J., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20 (2005) 1905-1911
31. Cosman F., Nieves J., Woelfert L., Shen V., and Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13 (1998) 1051-1055
32. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., and Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349 (2003) 1216-1226
33. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 (2003) 1207-1215